EUVIMEDEUVIMED entdecken
Evaluationsstudie

Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection

Suresh Ponnuvel, Hussain Ali, Arul Prakash, Runal John Steve iD, Bakthalal Singh, Anne George Cherian, Ashish Goel, Uday George Zachariah, Chundamannil Eapen Eapen, Carsten Buenning, David J Daghfal, Rajesh Kannangai iD und 2 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70307 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Suresh Ponnuvel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Virology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Hepatitis C Antibodies, Hepatitis C, Hepacivirus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: This study was funded by Abbott Laboratories, Abbott Park, Illinois 60064-3500., Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

World Health Organization recommends anti‐HCV antibody testing for primary screening to be followed by HCV‐RNA. However, current serological assays are prone to false‐positive results. We ascertained the ability of the newly developed Abbott Alinity‐i anti‐HCV Next assay (Research‐Use‐Only) to resolve false‐positives and profiled its performance edges. Samples ( n = 2186) received from January to June 2024 were subjected to anti‐HCV testing using Architect and anti‐HCV Next (Abbott), and LIAISON XL MUREX HCV antibody assays. Samples were categorized based on the signal to cutoff (S/CO) of on‐market anti‐HCV assays (Architect and Liaison) as negative Architect

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C AntibodiesHepatitis CHepacivirusHumansRNA, ViralSensitivity and SpecificityFalse Positive ReactionsHepatitis C Antigens

Stichwörter der Autor:innen

flavivirushepatitis C virusimmunologic techniques

Substanzen

Hepatitis C AntibodiesRNA, ViralHepatitis C Antigens

Autor:innen und Institutionen

  • Department of Clinical Virology, Christian Medical College, Vellore, India.
  • Abbott Diagnostics, Abbott Park, Illinois, USA.
  • Department of Community Health and Development, Christian Medical College, Vellore, India.
  • Department of Hepatology, Ranipet Campus, Christian Medical College, Vellore, India.

ORCID-Profile: Runal John Steve, Rajesh Kannangai, Gnanadurai John Fletcher

Förderung

  • This study was funded by Abbott Laboratories, Abbott Park, Illinois 60064-3500.
  • Abbott Laboratories

Zitieren

APA

Ponnuvel, S., Ali, H., Prakash, A., John Steve, R., Singh, B., Cherian, A. G., Goel, A., Zachariah, U. G., Eapen Eapen, C., Buenning, C., Daghfal, D. J., Kannangai, R., Abraham, P., & John Fletcher, G. (2025). Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.70307

Vancouver

Ponnuvel S, Ali H, Prakash A, John Steve R, Singh B, Cherian AG, et al. Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection. Journal of Medical Virology. 2025. doi:10.1002/jmv.70307

BibTeX
@article{Ponnuvel2025,
  author = {Ponnuvel, Suresh and Ali, Hussain and Prakash, Arul and John Steve, Runal and Singh, Bakthalal and Cherian, Anne George and Goel, Ashish and Zachariah, Uday George and Eapen Eapen, Chundamannil and Buenning, Carsten and Daghfal, David J and Kannangai, Rajesh and Abraham, Priya and John Fletcher, Gnanadurai},
  title = {Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70307}
}
Kostenlos starten →